» Articles » PMID: 22336288

Crohn's Disease Patients Have More IgG-binding Fecal Bacteria Than Controls

Overview
Date 2012 Feb 17
PMID 22336288
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

In Crohn's disease (CD), chronic gut inflammation leads to loss of mucosal barrier integrity. Subsequent leakage of IgG to the gut could produce an increase of IgG coating of intestinal bacteria. We investigated if there is more IgG coating in patients than in volunteers and whether this is dependent on the host IgG response or on the gut bacteria. Fecal and serum samples were obtained from 23 CD patients and 11 healthy volunteers. Both the in vivo IgG-coated fecal bacteria and in vitro IgG coating after serum addition were measured by flow cytometry and related to disease activity. The bacterial composition in feces was determined using fluorescence in situ hybridization. The IgG-binding capacities of Escherichia coli strains isolated from feces of patients and volunteers were assessed. The results showed that the in vivo IgG-coated fraction of fecal bacteria of patients was slightly larger than that of volunteers but significantly larger after incubation with either autologous or heterologous serum. This was dependent on the bacteria and independent of disease activity or the serum used. The presence of more Enterobacteriaceae and fewer faecalibacteria in patient feces was confirmed. E. coli isolates from patients bound more IgG than isolates from volunteers (P < 0.05) after the addition of autologous serum. Together, these results indicate that CD patients have more IgG-binding gut bacteria than healthy volunteers. We showed that the level of IgG coating depends on the bacteria and not on the serum used. Furthermore, CD patients have a strong specific immune response to their own E. coli bacteria.

Citing Articles

Diverse vaginal microbiota in healthy Japanese women: a combined relative and quantitative analyses.

Ito M, Kataoka M, Sato Y, Nachi H, Nomoto K, Okada N Front Cell Infect Microbiol. 2025; 14:1487990.

PMID: 39967801 PMC: 11832463. DOI: 10.3389/fcimb.2024.1487990.


The interrelation between microbial immunoglobulin coating, vaginal microbiota, ethnicity, and preterm birth.

Schuster H, Breedveld A, Matamoros S, van Eekelen R, Painter R, Kok M Microbiome. 2024; 12(1):99.

PMID: 38802950 PMC: 11131309. DOI: 10.1186/s40168-024-01787-z.


Distinct roles for LTalpha3 and LTalpha1beta2 produced by B cells contribute to their multi-faceted impact on ileitis.

Randolph G, Erlich E, Czepielewski R, Field R, Dunning T, Saleh L Res Sq. 2024; .

PMID: 38464070 PMC: 10925464. DOI: 10.21203/rs.3.rs-3962916/v1.


Investigating Antibody Reactivity to the Intestinal Microbiome in Severe Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): A Feasibility Study.

Seton K, Defernez M, Telatin A, Tiwari S, Savva G, Hayhoe A Int J Mol Sci. 2023; 24(20).

PMID: 37895005 PMC: 10607161. DOI: 10.3390/ijms242015316.


Intestinal colonization regulates systemic anti-commensal immune sensitivity and hyperreactivity.

Burkhard R, Koegler M, Brown K, Wilson K, Mager L, Zucoloto A Front Immunol. 2023; 14:1030395.

PMID: 37283756 PMC: 10239946. DOI: 10.3389/fimmu.2023.1030395.


References
1.
Poullis A, Foster R, Northfield T, Mendall M . Review article: faecal markers in the assessment of activity in inflammatory bowel disease. Aliment Pharmacol Ther. 2002; 16(4):675-81. DOI: 10.1046/j.1365-2036.2002.01196.x. View

2.
Sokol H, Seksik P, Furet J, Firmesse O, Nion-Larmurier I, Beaugerie L . Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm Bowel Dis. 2009; 15(8):1183-9. DOI: 10.1002/ibd.20903. View

3.
Franks A, Harmsen H, Raangs G, Jansen G, Schut F, Welling G . Variations of bacterial populations in human feces measured by fluorescent in situ hybridization with group-specific 16S rRNA-targeted oligonucleotide probes. Appl Environ Microbiol. 1998; 64(9):3336-45. PMC: 106730. DOI: 10.1128/AEM.64.9.3336-3345.1998. View

4.
Roseth A, Aadland E, Jahnsen J, Raknerud N . Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion. 1997; 58(2):176-80. DOI: 10.1159/000201441. View

5.
Poulsen L, Licht T, Rang C, Krogfelt K, Molin S . Physiological state of Escherichia coli BJ4 growing in the large intestines of streptomycin-treated mice. J Bacteriol. 1995; 177(20):5840-5. PMC: 177407. DOI: 10.1128/jb.177.20.5840-5845.1995. View